FGF21 and metabolic dysfunction-associated steatohepatitis: In addition, a phase 2b controlled trial is currently underway for the use of Pegasofermin—FGF-21 recombinant analogue for patients with histo-pathologically confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis.